JPC0323

JPC0323, also known as N-(1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)oleamide, is a dual serotonin 5-HT_2C and 5-HT_2A receptor positive allosteric modulator related to oleamide.^[1][2] It showed negligible affinity for roughly 50 other targets and did not bind to the orthosteric sites of these receptors.^[1][2] The drug does not affect the serotonin 5-HT_2B receptor.^[1][2]

Other namesJPC-0323; N-(1,3-Dihydroxy-2-(hydroxymethyl)propan-2-yl)oleamide

Drug classSerotonin 5-HT_2C and 5-HT_2A receptor positive allosteric modulator

ATC code

• None

CAS Number

• 5972-45-2

Quick facts Clinical data, Other names ...

JPC0323

Clinical data
Other names	JPC-0323; N-(1,3-Dihydroxy-2-(hydroxymethyl)propan-2-yl)oleamide
Drug class	Serotonin 5-HT2C and 5-HT2A receptor positive allosteric modulator
ATC code	None
Identifiers
IUPAC name (Z)-N-[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]octadec-9-enamide
CAS Number	5972-45-2
PubChem CID	6453844
ChemSpider	4956192
ChEMBL	ChEMBL5397931
CompTox Dashboard (EPA)	DTXSID201175111
Chemical and physical data
Formula	C22H43NO4
Molar mass	385.589 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCCCCCCC/C=C\CCCCCCCC(=O)NC(CO)(CO)CO
InChI InChI=1S/C22H43NO4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(27)23-22(18-24,19-25)20-26/h9-10,24-26H,2-8,11-20H2,1H3,(H,23,27)/b10-9- Key:JLFKELVBPUSMGW-KTKRTIGZSA-N

Close

JPC0323 showed favorable pharmacokinetic properties in preclinical research.^[1][2] It produced hypolocomotion in a serotonin 5-HT_2C receptor-dependent but not serotonin 5-HT_2A receptor-dependent manner in rats, suggesting that it might be a preferential serotonin 5-HT_2C receptor positive allosteric modulator in vivo.^[1][2] The drug was not assessed in terms of head-twitch response, an animal behavioral proxy of psychedelic effects.^[2] It is unknown whether it might have hallucinogenic effects via serotonin 5-HT_2A receptor potentiation, but its developers speculated that it might have reduced potential in this regard compared to orthosteric agonists.^[2]

JPC0323 was derived as an analogue of the fatty acid amide oleamide and was first described in the scientific literature by 2023.^[1][2] It was described as a "first-in-class" dual serotonin 5-HT_2C and 5-HT_2A receptor positive allosteric modulator.^[2]